Cargando…

Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone

INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Nigel P, Aedo, Socrates, Villalon, Ricardo, Albarran, Vidal, Orrego, Shenda, Guzman, Eghon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652547/
https://www.ncbi.nlm.nih.gov/pubmed/33209110
http://dx.doi.org/10.3332/ecancer.2020.1119
_version_ 1783607711292719104
author Murray, Nigel P
Aedo, Socrates
Villalon, Ricardo
Albarran, Vidal
Orrego, Shenda
Guzman, Eghon
author_facet Murray, Nigel P
Aedo, Socrates
Villalon, Ricardo
Albarran, Vidal
Orrego, Shenda
Guzman, Eghon
author_sort Murray, Nigel P
collection PubMed
description INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types and kinetics of relapse. METHODS AND PATIENTS: One month after surgery, blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anti-carcinoembryonic antigen (CEA). Follow-up was for up to 5 years or relapse. Disease-free survival curves using Kaplan–Meier (DFS) and restricted mean disease-free survival times (RMST) were calculated for three prognostic groups: A: MRD (−), B: mM (+) CTC (−) MRD and C: CTC (+) MRD. RESULTS: One hundred and eighty-one patients (82 men) have participated, mean age was 68 years and median follow-up was 4.04 years (A (N = 105), B (N = 36) and C (N = 40)). For the whole cohort of 5 years, DFS was 70%, median DFS has not reached (Groups A: 98%, B: 63% and C: 7%) and median DFS for Groups A and B have not reached. RMST for the whole cohort of 4.1 years, Group A was 4.9 years, B was 4.1 years and C was 1.7 years. Serum CEA was significantly higher in Group C. No significant differences for sex, age or high-risk adverse prognostic factors between groups were detected. CONCLUSIONS: MRD subtypes define relapse patterns and may be useful to define the risk of relapse in stage II CC patients, in which patients may benefit or not from additional therapy and warrants further studies with a larger number of patients.
format Online
Article
Text
id pubmed-7652547
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-76525472020-11-17 Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone Murray, Nigel P Aedo, Socrates Villalon, Ricardo Albarran, Vidal Orrego, Shenda Guzman, Eghon Ecancermedicalscience Research INTRODUCTION: Twenty-five percent of stage II colon cancer (CC) patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery. We hypothesise that subtypes of MRD, defined by circulating tumour cells (CTCs) and bone marrow micrometastasis (mM), have different types and kinetics of relapse. METHODS AND PATIENTS: One month after surgery, blood and bone marrow samples were taken to detect CTCs and mM using immunocytochemistry with anti-carcinoembryonic antigen (CEA). Follow-up was for up to 5 years or relapse. Disease-free survival curves using Kaplan–Meier (DFS) and restricted mean disease-free survival times (RMST) were calculated for three prognostic groups: A: MRD (−), B: mM (+) CTC (−) MRD and C: CTC (+) MRD. RESULTS: One hundred and eighty-one patients (82 men) have participated, mean age was 68 years and median follow-up was 4.04 years (A (N = 105), B (N = 36) and C (N = 40)). For the whole cohort of 5 years, DFS was 70%, median DFS has not reached (Groups A: 98%, B: 63% and C: 7%) and median DFS for Groups A and B have not reached. RMST for the whole cohort of 4.1 years, Group A was 4.9 years, B was 4.1 years and C was 1.7 years. Serum CEA was significantly higher in Group C. No significant differences for sex, age or high-risk adverse prognostic factors between groups were detected. CONCLUSIONS: MRD subtypes define relapse patterns and may be useful to define the risk of relapse in stage II CC patients, in which patients may benefit or not from additional therapy and warrants further studies with a larger number of patients. Cancer Intelligence 2020-10-08 /pmc/articles/PMC7652547/ /pubmed/33209110 http://dx.doi.org/10.3332/ecancer.2020.1119 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Murray, Nigel P
Aedo, Socrates
Villalon, Ricardo
Albarran, Vidal
Orrego, Shenda
Guzman, Eghon
Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title_full Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title_fullStr Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title_full_unstemmed Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title_short Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone
title_sort subtypes of minimal residual disease and outcome for stage ii colon cancer treated by surgery alone
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652547/
https://www.ncbi.nlm.nih.gov/pubmed/33209110
http://dx.doi.org/10.3332/ecancer.2020.1119
work_keys_str_mv AT murraynigelp subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone
AT aedosocrates subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone
AT villalonricardo subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone
AT albarranvidal subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone
AT orregoshenda subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone
AT guzmaneghon subtypesofminimalresidualdiseaseandoutcomeforstageiicoloncancertreatedbysurgeryalone